11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults.

Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the company said.

Price: 270.34, Change: +0.96, Percent Change: +0.36